
    
      This is a Phase 2, double-blind, randomized, placebo-controlled, parallel group study.
      Approximately 60 male or female subjects aged 18 years or older with one shallow foot ulcer
      and mild/moderate ischemia due to peripheral artery disease (PAD) will be randomized in a
      1:1:1 ratio to one of 3 treatment groups:

        -  4.0 mg AMG0001 intramuscular (IM) (n = 20)

        -  8.0 mg AMG0001 IM (n = 20)

        -  Placebo IM (n = 20)
    
  